News
RNXT
1.262
+0.17%
0.002
Weekly Report: what happened at RNXT last week (1118-1122)?
Weekly Report · 4d ago
RenovoRx Expands TIGeR-PaC Study with Northwell Health Cancer Institute to Evaluate Innovative Treatment for Locally Advanced Pancreatic Cancer
Barchart · 11/20 17:52
RenovoRx announces NHCI is enrolling patients for Phase III TIGeR-PaC trial
TipRanks · 11/20 13:50
RenovoRx Announces That The Northwell Health Cancer Institute In New Hyde Park, NY Is Enrolling Patients With Locally Advanced Pancreatic Cancer In The Co's Ongoing Phase III TiGeR-PaC Clinical Trial; NHCI Joins Esteemed Clinical Sites Throughout The U.S. Participating In The Study
Benzinga · 11/20 13:47
NORTHWELL HEALTH CANCER INSTITUTE LAUNCHES PATIENT ENROLLMENT IN RENOVORX’S ONGOING PIVOTAL PHASE III TIGER-PAC CLINICAL TRIAL
Reuters · 11/20 13:45
Weekly Report: what happened at RNXT last week (1111-1115)?
Weekly Report · 11/18 11:00
Positive Outlook for RenovoRx: Promising TIGeR-PaC Phase 3 Trial Results and Innovative Drug Delivery Platform Drive Buy Rating
TipRanks · 11/15 15:15
RenovoRx reports Q3 results
Seeking Alpha · 11/14 19:08
RenovoRx Q3 EPS $(0.10), Inline
Benzinga · 11/14 13:23
RenovoRx reports Q3 net loss $2.5M vs $1.4M last year
TipRanks · 11/14 13:12
RENOVORX REPORTS THIRD QUARTER 2024 FINANCIAL RESULTS AND OPERATIONAL HIGHLIGHTS
Reuters · 11/14 13:00
Press Release: RenovoRx Reports Third Quarter 2024 Financial Results and Operational Highlights
Dow Jones · 11/14 13:00
Weekly Report: what happened at RNXT last week (1104-1108)?
Weekly Report · 11/11 11:12
Weekly Report: what happened at RNXT last week (1028-1101)?
Weekly Report · 11/04 11:10
Weekly Report: what happened at RNXT last week (1021-1025)?
Weekly Report · 10/28 11:02
Weekly Report: what happened at RNXT last week (1014-1018)?
Weekly Report · 10/21 10:59
Weekly Report: what happened at RNXT last week (1007-1011)?
Weekly Report · 10/14 11:25
Weekly Report: what happened at RNXT last week (0930-1004)?
Weekly Report · 10/07 11:15
Weekly Report: what happened at RNXT last week (0923-0927)?
Weekly Report · 09/30 11:09
RENOVORX INCREASES PRODUCTION OF FDA-CLEARED RENOVOCATH® DELIVERY SYSTEM IN RESPONSE TO STRONG DEMAND FROM ONCOLOGY AND INTERVENTIONAL RADIOLOGY PHYSICIANS
Reuters · 09/25 12:30
More
Webull provides a variety of real-time RNXT stock news. You can receive the latest news about Renovorx Inc through multiple platforms. This information may help you make smarter investment decisions.
About RNXT
RenovoRx, Inc. is a clinical-stage biopharmaceutical company. The Company is developing targeted combination therapies for high unmet medical needs with a goal of improving therapeutic outcomes for cancer patients undergoing treatment. Its Trans-Arterial Micro-Perfusion (TAMP) therapy platform is designed to ensure precise therapeutic delivery to directly target the tumor while potentially minimizing a therapy’s toxicities versus systemic intravenous therapy. Its portfolio of cancer therapies is based on its lead product candidate, RenovoGem (gemcitabine delivered via its delivery system). Its phase III lead product candidate, RenovoGem, is a novel oncology drug-device combination product. RenovoGem is being evaluated for the treatment of locally advanced pancreatic cancer (LAPC) by the Center for Drug Evaluation and Research. Its phase III registrational trial of RenovoGem for the treatment of LAPC is called TIGeR-PaC.